{"id":869379,"date":"2025-07-14T16:21:34","date_gmt":"2025-07-14T20:21:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\/"},"modified":"2025-07-14T16:21:34","modified_gmt":"2025-07-14T20:21:34","slug":"wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\/","title":{"rendered":"Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, July  14, 2025  (GLOBE NEWSWIRE) &#8212; Wolf Popper LLP is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. (\u201cCapricor\u201d) common stock (NASDAQ: CAPR).<\/p>\n<p align=\"justify\">Capricor is a clinical-stage drug company and its lead product candidate is Deramiocel, which is used to treat cardiomyopathy, a weakening of the heart in people with Duchenne muscular dystrophy. Capricor\u2019s Phase 2 HOPE-2 clinical trial was completed in 2021.<\/p>\n<p align=\"justify\">On September 24, 2024, Capricor announced it was filing a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for the approval of Deramiocel. In the press release, Capricor said it had multiple in-depth meetings with the FDA. This announcement caused Capricor\u2019s stock price to jump from $5.97 per share to $9.10 per share. On May 13, 2025, Capricor announced its first quarter 2025 results, referencing that the company \u201cRecently completed mid-cycle review meeting with FDA with no significant deficiencies identified\u2026.\u201d<\/p>\n<p align=\"justify\">Before the market opened on July 11, 2025, Capricor announced it received a Complete Response Letter [CRL] from the FDA regarding its BLA for Deramiocel. The press release said the FDA was unable to approve the BLA, citing that \u201cthe BLA does not meet the statutory requirement for substantial evidence of effectiveness and the need for additional clinical data. The CRL also referenced certain outstanding items in Chemistry, Manufacturing, and Controls (CMC) section of the application.\u2026\u201d<\/p>\n<p align=\"justify\">On this news, Capricor\u2019s stock price fell $3.76 per share to $7.64 on July 11, 2025, down 33.0% on very heavy volume.<\/p>\n<p align=\"justify\">Investors who suffered losses trading in Capricor common stock and who would like to discuss the investigation should contact Adam Savett at (212) 451-9655, or asavett@wolfpopper.com.<\/p>\n<p align=\"justify\">Wolf Popper has successfully recovered billions of dollars for defrauded investors. Wolf Popper\u2019s reputation and expertise have been repeatedly recognized by courts that have appointed the firm to major positions in securities litigation. For more information about Wolf Popper, please visit the Firm\u2019s website at www.wolfpopper.com.<\/p>\n<p align=\"justify\">May Be Considered Attorney Advertising in Certain Jurisdictions. <br \/>Prior Results Do Not Guarantee a Similar Outcome.<\/p>\n<p align=\"justify\">Wolf Popper LLP<br \/>Adam Savett. Esq.<br \/>845 Third Avenue<br \/>New York, NY 10022<br \/>Tel.: (212) 451-9655<br \/>Email: asavett@wolfpopper.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5NDI0MCM3MDQ3NDgyIzIwMTc2NDY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YjEyZDk2MmQtYTUwNi00OGU4LWEzYTAtZjEyNzJmMjgxN2UyLTEwMjkyMTktMjAyNS0wNy0xNC1lbg==\/tiny\/Wolf-Popper-LLP.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) &#8212; Wolf Popper LLP is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. (\u201cCapricor\u201d) common stock (NASDAQ: CAPR). Capricor is a clinical-stage drug company and its lead product candidate is Deramiocel, which is used to treat cardiomyopathy, a weakening of the heart in people with Duchenne muscular dystrophy. Capricor\u2019s Phase 2 HOPE-2 clinical trial was completed in 2021. On September 24, 2024, Capricor announced it was filing a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for the approval of Deramiocel. In the press release, Capricor said it had multiple in-depth meetings with the FDA. This announcement caused Capricor\u2019s stock price to jump from $5.97 per &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-869379","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) &#8212; Wolf Popper LLP is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. (\u201cCapricor\u201d) common stock (NASDAQ: CAPR). Capricor is a clinical-stage drug company and its lead product candidate is Deramiocel, which is used to treat cardiomyopathy, a weakening of the heart in people with Duchenne muscular dystrophy. Capricor\u2019s Phase 2 HOPE-2 clinical trial was completed in 2021. On September 24, 2024, Capricor announced it was filing a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for the approval of Deramiocel. In the press release, Capricor said it had multiple in-depth meetings with the FDA. This announcement caused Capricor\u2019s stock price to jump from $5.97 per &hellip; Continue reading &quot;Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-14T20:21:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5NDI0MCM3MDQ3NDgyIzIwMTc2NDY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors\",\"datePublished\":\"2025-07-14T20:21:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\\\/\"},\"wordCount\":356,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5NDI0MCM3MDQ3NDgyIzIwMTc2NDY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\\\/\",\"name\":\"Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5NDI0MCM3MDQ3NDgyIzIwMTc2NDY=\",\"datePublished\":\"2025-07-14T20:21:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5NDI0MCM3MDQ3NDgyIzIwMTc2NDY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5NDI0MCM3MDQ3NDgyIzIwMTc2NDY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\/","og_locale":"en_US","og_type":"article","og_title":"Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors - Market Newsdesk","og_description":"NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) &#8212; Wolf Popper LLP is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. (\u201cCapricor\u201d) common stock (NASDAQ: CAPR). Capricor is a clinical-stage drug company and its lead product candidate is Deramiocel, which is used to treat cardiomyopathy, a weakening of the heart in people with Duchenne muscular dystrophy. Capricor\u2019s Phase 2 HOPE-2 clinical trial was completed in 2021. On September 24, 2024, Capricor announced it was filing a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for the approval of Deramiocel. In the press release, Capricor said it had multiple in-depth meetings with the FDA. This announcement caused Capricor\u2019s stock price to jump from $5.97 per &hellip; Continue reading \"Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-14T20:21:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5NDI0MCM3MDQ3NDgyIzIwMTc2NDY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors","datePublished":"2025-07-14T20:21:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\/"},"wordCount":356,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5NDI0MCM3MDQ3NDgyIzIwMTc2NDY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\/","name":"Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5NDI0MCM3MDQ3NDgyIzIwMTc2NDY=","datePublished":"2025-07-14T20:21:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5NDI0MCM3MDQ3NDgyIzIwMTc2NDY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5NDI0MCM3MDQ3NDgyIzIwMTc2NDY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-capricor-therapeutics-inc-investors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/869379","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=869379"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/869379\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=869379"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=869379"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=869379"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}